Richard J. Hawkins
Richard J. Hawkins's purchase track record
Richard J. Hawkins has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/20/2025 | SVRA | $99K | +71.4% | +193.7% | +14.5% |
| 9/12/2024 | CNSY | $15K | pending | pending | — |
| 5/8/2024 | CNSY | $10K | pending | pending | — |
| 3/3/2023 | CNSY | $1K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Savara Stock Mentioned Among Gainers in Market Roundup. Savara Inc. was included in a recent market roundup highlighting stocks that moved higher on Wednesday. The company's shares are currently trading near a key support level, which may have contributed to the short-term price movement noted in the report. This mention reflects general market activity rather than a specific corporate announcement.
Transaction History
| CNSY | ▲ Buy | Option Exercise | 921 | $0 | 10/1/2026 | View on chart |
| CNSY | ▲ Buy | Option Exercise | 922 | $0 | 7/1/2026 | View on chart |
| SVRA | ▲ Buy | Grant | 40,000 | $0 | 12/9/2025 | View on chart |
| SVRA | ▲ Buy | Option Exercise | 5,860 | $9K | 11/14/2025 | View on chart |
| SVRA | ▲ Buy | Open Market | 48,225 | $99K | 6/20/2025 | View on chart |
| SVRA | ▼ Sell | Open Market | 8,000 | $27K | 12/16/2024 | View on chart |
| SVRA | ▲ Buy | Grant | 40,000 | $0 | 12/12/2024 | View on chart |
| CNSY | ▲ Buy | Open Market | 4,000 | $6K | 9/13/2024 | View on chart |
| CNSY | ▲ Buy | Open Market | 6,285 | $9K | 9/12/2024 | View on chart |
| CNSY | ▲ Buy | Open Market | 4,902 | $10K | 5/8/2024 | View on chart |
| SVRA | ▲ Buy | Grant | 22,500 | $0 | 12/14/2023 | View on chart |
| SVRA | ▲ Buy | Option Exercise | 10,841 | $9K | 12/11/2023 | View on chart |
| CNSY | ▲ Buy | Open Market | 1 | $1K | 3/3/2023 | View on chart |
| SVRA | ▲ Buy | Option Exercise | 1,172 | $762 | 12/7/2022 | View on chart |
| SVRA | ▲ Buy | Option Exercise | 728 | $400 | 12/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Cerenome projects $1.55M in Q3 CNSide billings
Cerenome expects $1.55 million in gross billings for its CNSide platform in the third quarter. The company also announced it will hold a business update call on September 30, 2026, to discuss progress in its diagnostic division. This update provides specific revenue expectations for the company's main product line.
Cerenome projects $1.55M in Q3 CNSide billings. Cerenome expects $1.55 million in gross billings for its CNSide platform in the third quarter. The company also announced it will hold a business update call on September 30, 2026, to discuss progress in its diagnostic division. This update provides specific revenue expectations for the company's main product line.